Similar Search Results

Pharmaceutical advertising and Medicare Part D

Lakdawalla, Darius; Sood, Neeraj; Gu, Qian - In: Journal of health economics 32 (2013) 6, pp. 1356-1367

Persistent link: https://www.econbiz.de/10010425165

The economics of alternative payment models for pharmaceuticals

Hlávka, Jakub P.; Yu, Jeffrey C.; Goldman, Dana P.; … - In: The European journal of health economics 22 (2021) 4, pp. 559-569

Persistent link: https://www.econbiz.de/10012586512

Patient outcomes and cost effects of medicaid formulary restrictions on antidepressants

Seabury, Seth A.; Lakdawalla, Darius; Walter, Deborah; … - In: Forum for health economics & policy : an evolving … 17 (2014) 2, pp. 153-168

Persistent link: https://www.econbiz.de/10010458253

Innovation and the welfare effects of public drug insurance

Lakdawalla, Darius; Sood, Neeraj - In: Journal of public economics 93 (2009) 3/4, pp. 541-548

Persistent link: https://www.econbiz.de/10003841134

Market size and innovation : effects of Medicare Part D on pharmaceutical research and development

Blume-Kohout, Margaret E.; Sood, Neeraj - In: Journal of public economics 97 (2013) 1, pp. 327-336

Persistent link: https://www.econbiz.de/10009710440

The Welfare Effects of Public Drug Insurance

Lakdawalla, Darius - 2007

Rewarding inventors with inefficient monopoly power has long been regarded as the price of encouraging innovation. Public prescription drug insurance escapes that trade-off and achieves an elusive goal: lowering static deadweight loss, while simultaneously encouraging dynamic investments in...

Persistent link: https://www.econbiz.de/10012465145